Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study.

Gut and liver - 15 Jan 2017

Cho Eun Young, Yim Hyung Joon, Jung Young Kul, Suh Sang Jun, Seo Yeon Seok, Kim Ji Hoon, Kim Hong Soo, Lee Sae Hwan, Ahn Sang Hoon, Lee Jeong Il, Jeong Sook-Hyang, Kim Jin-Wook, Lee Jin-Woo, Kim In Hee, Kim Hyoung Su, Park Sang Jong, Lee Jeong Mi, Hwang Seong Gyu

Abstract excerpt

BACKGROUND/AIMS: Data are lacking regarding the management of chronic hepatitis B (CHB) with resistance to clevudine (CLV). This study evaluated the efficacy of different rescue therapies for CLV-resistant CHB. METHODS: Patients with CLV-resistant CHB were enrolled in the cohort, and all patients developed virologic breakthrough during CLV therapy and had confirmed-genotypic resistance to CLV (rtM204I mutation)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Disease Management

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Guanine

Share to Hepatitis B, Chronic

Share to Lamivudine

Share to Organophosphonates

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 27538443
DOI: 10.5009/gnl15597
PMCID: PMC5221870

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study.PMID 27538443Read ↗

Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B.Semantic proximity Read ↗

Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.Semantic proximity Read ↗

Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.Semantic proximity Read ↗

Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.Semantic proximity Read ↗

Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B.Semantic proximity Read ↗

Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy.Semantic proximity Read ↗

Identification and Characterization of Clevudine-Resistant Mutants of Hepatitis B Virus Isolated from Chronic Hepatitis B PatientsSemantic proximity Read ↗

Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.Semantic proximity Read ↗

Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis B.Semantic proximity Read ↗

Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B.Semantic proximity Read ↗

Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression.Semantic proximity Read ↗

Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.